An Expanding Toolbox: A Glimpse into Novel and Emerging Systemic Therapies for Metastatic Hormone Receptor-Positive, HER2-Negative Breast Cancer

An Expanding Toolbox: A Glimpse into Novel and Emerging Systemic Therapies for Metastatic Hormone Receptor-Positive, HER2-Negative Breast Cancer is organized by Efficient LLC.

Course Opens: 09/17/2025
Course Expires: 09/17/2026

Description:
The management of hormone receptor–positive (HR+), HER2–negative (HER2-) metastatic breast cancer (mBC) is evolving rapidly. CDK4/6 inhibitors (CDK4/6i) with endocrine therapy (ET) remain a standard first-line option, but growing adjuvant use means many patients now present with prior CDK4/6i exposure or ET resistance. This earlier resistance is reshaping molecular testing and treatment sequencing. At the same time, new biomarker-driven strategies are expanding opportunities for patients with targetable mutations (e.g., PIK3CA, AKT1) or ET resistance (e.g., ESR1). These agents show meaningful activity, though questions remain around optimal sequencing, patient selection, and clinical integration.

To explore the implications of these advances, this activity synthesizes insights from a survey of five BC specialists alongside discussion of consensus-based guidelines, pivotal phase 3 trial data, and ongoing research efforts. By integrating real-world practice patterns with the latest evidence, the program aims to equip oncology clinicians with practical strategies for optimizing care for their own patients with HR+/HER2– mBC.

Learning Objectives:
Upon completion of this activity, the learner should be able to:

• Identify the role of actionable biomarker mutations (e.g. ESR1, PIK3A, AKT1) in the selection of therapy for patients with HR+/HER2- mBC to improve individualized treatment selection
• Apply evidence-based strategies for managing and monitoring adverse effects (AEs) associated with novel ETs alone and in combination with other targeted therapies in HR+/HER2- mBC to improve patient tolerability, treatment adherence, and persistence
• Appraise clinical efficacy and safety data surrounding approved and emerging ETs alone and in combination with other targeted therapies in HR+/HER2- mBC, including their impact on patients with prior treatment resistance, to improve decision-making across practice settings.